A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

(2016) Bryan R. Haugen et al.   THYROID

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

(2015) Xiu-Xiu Chen et al.   Oncotarget

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

Cdk5 regulates multiple cellular events in neural development, function and disease

(2014) Takeshi Kawauchi   DEVELOPMENT GROWTH & DIFFERENTIATION

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

(2014) Robert N. Booher et al.   PLoS One

The Role of Cdk5 in Neuroendocrine Thyroid Cancer

(2013) Karine Pozo et al.   CANCER CELL

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

(2013) Ivana Gojo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting survivin in cancer

(2012) Dario C. Altieri   CANCER LETTERS

Why minimal is not optimal: Driving the mammalian cell cycle—and drug discovery—with a physiologic CDK control network

(2012) Karl A. Merrick et al.   CELL CYCLE

Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy

(2012) Shu-Fu Lin et al.   PLoS One

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

(2012) Robert C. Smallridge et al.   THYROID

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

(2011) Georg Feldmann et al.   CANCER BIOLOGY & THERAPY

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

(2011) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells

(2011) W. Fu et al.   MOLECULAR CANCER THERAPEUTICS

Physiological Relevance of Cell Cycle Kinases

(2011) Marcos Malumbres   PHYSIOLOGICAL REVIEWS

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Potential Utility and Limitations of Thyroid Cancer Cell Lines as Models for Studying Thyroid Cancer

(2009) Tania Pilli et al.   THYROID

Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification

(2008) Rebecca E. Schweppe et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early Development

(2008) D. O. Cowley et al.   MOLECULAR AND CELLULAR BIOLOGY